title: COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
abstract: Previous studies suggest that cyclooxygenase-2 (COX-2) expression may predict survival among patients with non-small cell lung cancer. COX-2 may interact with epidermal growth factor receptor (EGFR), suggesting that combined COX-2/EGFR expression may provide predictive value. The extent to which their independent or combined expression is associated with prognosis in women with adenocarcinoma of the lung is unknown. In the present study, we examined relationships between COX-2 expression (n = 238), EGFR expression (n = 158) and dual COX-2/EGFR expression (n = 157) and survival among women with adenocarcinoma of the lung. Overall survival was estimated by constructing Cox proportional hazards models adjusting for other significant variables and stratifying by stage at diagnosis and race. Clinical or demographic parameters were not associated with either COX-2 or EGFR expression. Patients with COX-2-positive tumors tended to have poorer prognosis than did patients with COX-2-negative tumors [hazard ratio (HR) 1.67, 95% confidence interval (CI) 1.01-2.78]. African-Americans with COX-2-positive tumors had a statistically non-significant higher risk of death than African-Americans with COX-2-negative tumors (HR 5.58, 95% CI 0.64-48.37). No association between COX-2 expression and survival was observed among Caucasians (HR 1.29, 95% CI 0.72-2.30). EGFR expression was associated with a 44% reduction in the risk of death (HR 0.56, 95% CI 0.32-0.98). COX-2-/EGFR+ tumor expression, but not COX-2+/EGFR+ tumor expression, was associated with survival when compared with other combined expression results. In conclusion, COX-2 and EGFR expression, but not combined COX-2+/EGFR+ expression, independently predict survival of women with adenocarcinoma of the lung.
authors.affiliation: Cancer Biology Program, Karmanos Cancer Institute, WayneState University School of Medicine, Detroit, MI 48201, USA. avandyk@med.wayne.edu
authors.forename: Alison L
authors.initials: AL
authors.lastname: Van Dyke
authors.forename: Michele L
authors.initials: ML
authors.lastname: Cote
authors.forename: Geoffrey M
authors.initials: GM
authors.lastname: Prysak
authors.forename: Gina B
authors.initials: GB
authors.lastname: Claeys
authors.forename: Angie S
authors.initials: AS
authors.lastname: Wenzlaff
authors.forename: Valerie C
authors.initials: VC
authors.lastname: Murphy
authors.forename: Fulvio
authors.initials: F
authors.lastname: Lonardo
authors.forename: Ann G
authors.initials: AG
authors.lastname: Schwartz
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate
chemical_list: D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D066246:ErbB Receptors